Cardiac performance has multiple dimensions. This SS-31 study emphasized a late-life diastolic deficit rather than a uniform improvement in every heart measurement. Primary report
What the report found
Eight weeks of SS-31 improved reported diastolic function in old mice, while fractional shortening was unchanged. Mitochondrial and protein-redox measures also shifted. A mitochondrial-targeted catalase intervention produced related functional findings, and SS-31 did not add the same cardiac benefit in the old catalase-expressing mice. Primary report
Our appraisal: nonadditivity is informative, not definitive
When two interventions do not add together, an overlapping mechanism is one possible explanation. Other possibilities include a ceiling on the outcome, inadequate sensitivity, or different limiting steps. The result can motivate a shared-pathway hypothesis without proving that the interventions are mechanistically identical.
The functional distinction also matters. Diastolic relaxation and a systolic measure should not be combined into a vague claim of complete cardiac rejuvenation. A negative or unchanged endpoint narrows the conclusion and helps define what a follow-up study should measure.
The experiment treated old animals, which makes the timing question different from lifelong prevention. Even so, selected reversal of an age-associated phenotype is not evidence that aging as a whole was reversed. Lifespan and other organ systems require separate outcomes.
Full review should inspect sex-specific experiments, small group sizes, repeated-measures methods, and persistence after treatment cessation. The paper contributes a functional and mechanistic aging observation in mice. It does not establish a therapy for healthy older people or justify translating experimental exposure into personal use.
Frequently asked questions
Was diastolic function measured?
Yes.
Did fractional shortening also improve?
It was not altered in the cited finding.
Was mitochondrial-targeted catalase examined?
Yes, in a mechanistic comparison.
Does nonadditivity prove identical mechanisms?
No.
Does one reversed phenotype mean all aging was reversed?
No.
Was this a human clinical trial?
No.
What should the conclusion name?
The specific cardiac function, animal population, timing, and mechanistic uncertainty.